As previously described, MYOM3 is present in sera from DMD patients and some animal models of DMD and is substantially decreased after dystrophin and muscle restoration, making MYOM3 a promising biomarker for monitoring therapeutic outcomes in DMD.27 Here, DMD is linked to Duchenne muscular dystrophy.